Engineered regulatory t cell
AssigneeUCL Business PLC
InventorsHans Stauss, Graham P. Wright, Jenny L. McGovern
Life of this patent
Estimating the term…
Abstract
The present invention relates to an engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a myelin basic protein (MBP) peptide or variant or fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule. The present invention further relates to methods for providing an engineered Treg and to methods and uses of said engineered Treg and vectors and kits of vectors encoding said Treg.
Claims24
An engineered regulatory T cell (Treg) comprising a T cell receptor (TCR) which is capable of specifically binding to a peptide which comprises MBP 111-129 (SEQ ID NO:
- 3) or variant with at least 90% identity to SEQ ID NO:
- 3 or a fragment thereof when the peptide is presented by a major histocompatibility complex (MHC) molecule.
An engineered Treg according to any preceding claim, wherein the TCR comprises an α chain and a β chain,
- wherein the α chain and the β chain each comprises three complementarity determining regions (CDRs) and the sequence of each CDR3 is as follows:
- CDR3α
- (SEQ ID NO:
- 5)
- TVYGGATNKLIFGTGTLLAVQPNIQNPD
- CDR3β
- (SEQ ID NO:
- 6)
- SARGGSYNSPLHFGNGTRLTVTE
- or a variant of those sequences having up to three amino acid changes.
An engineered Treg according to any preceding claim, wherein the constant region domains of the α chain and β chain of the TCR each comprise an additional cysteine residue, enabling the formation of an extra disulphide bond between the α chain and the β chain.
An engineered Treg according to any preceding claim wherein:
- (a) the α chain of the TCR comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:
- 13;
- and
- (b) the β chain of the TCR comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:
- 14.
An engineered Treg according to any preceding claim, wherein the Treg is derived from a T cell isolated from a subject.
A pharmaceutical composition comprising an engineered Treg according to any preceding claim.
An engineered Treg or pharmaceutical composition according to any preceding claim for use in treating a disease.
Dependencies are inferred from the claim text.